- UPDATE: Due to an error in which unrelated text was accidentally transposed into this item, the original version of this item misquoted Leerink Swann's note to investors. BNET regrets the error.
In fact, Merck believes the White House and Sen. Max Baucus, D-Mont., will cut the public option from the final bill, Leerink's Seamus Fernandez and Kathryn C. Alexander report. In a note to investors describing their meeting with CEO Richard Clark and president Kenneth Frazier, they said:
On the subject of healthcare reform, management feels that big pharma still has a seat at the table and the industry still supports Senator Baucus's bill. MRK management is hopeful that the $80B pharma deal will remain in the final bill that is passed and is not in favor of a public option. Management thinks that the deal that was struck between big pharma, Baucus, and the White House will hold. PhRMA's support for the $80B deal assumed that there would not be a public plan. The public option concerns MRK management because of what it could do to severely limit drug pricing power in the United States via imposed price constraints instead of allowing for free market pricing and innovation to foster competition.In a statement to BNET Merck said:
... issues related to a government plan were not part of those negotiations and not part of our agreement to provide substantial system savings to support health reform. It is our hope that the White House and Senator Baucus will continue to honor the agreement for the amount of the industry contribution and the mechanisms for that contribution/savings.Merck's position -- that it opposes the public option -- is consistent with the rest of Big Pharma's. The industry is against any reform that would allow the government to negotiate drug prices.
Merck's full statement follows the jump.
Leerink put out a longer statement elaborating on its take-away from the Merck meeting. You can download that here.
- Conservatives Spread Rumor That Healthcare Reform Mandates Microchip Implants
- Sanofi's Viehbacher Backs Health Reform; May Change Company's Name
- Why Allergan and Medicis Should Embrace the "Botox Tax" in Senate Health Bill
- Peter Pitts' CMPI Targeted Over Anti-Healthcare Reform Video Game
- Sen. Franken Wants to End Tax Deductions on Drug Promotion
- What the Bosses of AZ, Novartis and Schering Didn't Say in Their Healthcare Roundtable
- Amgen, AstraZeneca and Their Lobbyists Were Lead Givers to Baucus' Warchest
- Sanofi Also Linked to FreedomWorks, Group That Urged Healthcare Town Hall Disruptions; Armey Quits DLA Piper